Kim Y.W. et al. [49] showed a significant improvement in sensitivity in the diagnosis of ovarian cancer using a combination of three serum biomarkers: CA125, transthyretin and apolipoprotein A1 (ApoAI). This evidence concerns the gene MUC16 and ovarian cancer.